<p>Jaypirca is a cancer medicine used to treat adults with mantle cell lymphoma (MCL) or chronic lymphocytic leukaemia (CLL), two types of cancer of B cells (a type of white blood cell). It is used in patients whose cancer has come back (relapsed) or no longer responds to treatment (refractory), and who had previously received a type of cancer medicine called a Bruton’s tyrosine kinase (BTK) inhibitor.</p><p>Jaypirca contains the active substance pirtobrutinib.</p>
Therapeutic Indication
<div class="subsection mt-3-5"> <h3>Therapeutic indication</h3><p>Jaypirca as monotherapy is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) who have been previously treated with a Bruton’s tyrosine kinase (BTK) inhibitor.</p><p>Jaypirca as monotherapy is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukaemia (CLL) who have been previously treated with a BTK inhibitor.</p></div>
Therapeutic Area (MeSH)
ATC Code
L01
ATC Item
N/A
Pharmacotherapeutic Group
N/A
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| pirtobrutinib | N/A | pirtobrutinib |
EMA Name
Jaypirca
Medicine Name
Jaypirca
Aliases
N/ANo risk management plan link.
